| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
104,310,000 |
| Market
Cap: |
4.48(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$41.73 - $42.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 779 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Syneos Health is a holding company. Through its subsidiaries, Co. is a biopharmaceutical solutions organization. Co. has two segments: Clinical Solutions, which provides a variety of services spanning Phase I to Phase IV of clinical development, including global studies, as well as individual service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process; and Commercial Solutions, which provides commercialization services, including deployment solutions, communication solutions (public relations, advertising, and medical communications), and consulting services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
23,703 |
| Total Sell Value |
$0 |
$0 |
$0 |
$1,745,443 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
10 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  1829356 Ontario Ltd |
Director |
– • • |
2016-05-06 |
4 |
S |
$45.12 |
$176,552,124 |
I/I |
(3,912,946) |
6,389,765 |
|
- |
|
| Inc Research Mezzanine Co-Invest, Llc |
10% Owner |
– – • |
2016-05-06 |
4 |
S |
$45.12 |
$184,407,876 |
I/I |
(4,087,054) |
6,674,085 |
|
- |
|
| Ogle James T. |
Director |
– • – |
2016-04-18 |
4 |
AS |
$50.00 |
$5,740,300 |
D/D |
(114,806) |
178,386 |
|
- |
|
| Ogle James T. |
Director |
– • – |
2016-04-18 |
4 |
OE |
$8.45 |
$970,111 |
D/D |
114,806 |
293,192 |
|
- |
|
| Macdonald D. Jamie |
Chief Executive Officer |
• • – |
2016-04-12 |
4 |
AS |
$48.00 |
$4,544,400 |
D/D |
(94,675) |
79,226 |
|
- |
|
| Macdonald D. Jamie |
Chief Executive Officer |
• • – |
2016-04-12 |
4 |
OE |
$10.57 |
$1,000,715 |
D/D |
94,675 |
114,729 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-04-01 |
4 |
AS |
$40.78 |
$367,038 |
D/D |
(9,000) |
47,282 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-04-01 |
4 |
OE |
$8.45 |
$76,050 |
D/D |
9,000 |
56,282 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-03-01 |
4 |
AS |
$39.85 |
$358,677 |
D/D |
(9,000) |
47,282 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-03-01 |
4 |
OE |
$8.45 |
$76,050 |
D/D |
9,000 |
56,282 |
|
- |
|
| Breckon Robert W |
Director |
– • – |
2016-02-04 |
4 |
AS |
$38.58 |
$155,381 |
D/D |
(3,882) |
8,432 |
|
- |
|
| Breckon Robert W |
Director |
– • – |
2016-02-04 |
4 |
OE |
$8.45 |
$23,550 |
D/D |
2,787 |
11,219 |
|
- |
|
| Rush Gregory S |
Executive VP and CFO |
• – – |
2016-02-01 |
4 |
AS |
$40.13 |
$714,861 |
D/D |
(17,752) |
20,132 |
|
- |
|
| Rush Gregory S |
Executive VP and CFO |
• – – |
2016-02-01 |
4 |
OE |
$16.06 |
$285,097 |
D/D |
17,752 |
37,884 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-02-01 |
4 |
AS |
$40.45 |
$365,152 |
D/D |
(9,000) |
47,282 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-02-01 |
4 |
OE |
$8.45 |
$76,050 |
D/D |
9,000 |
56,282 |
|
- |
|
| Rush Gregory S |
Executive VP and CFO |
• – – |
2016-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
20,132 |
|
- |
|
| Gaenzle Christopher L |
CAO, GC & Sec |
• – – |
2016-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
9,050 |
16,341 |
|
- |
|
| Macdonald Alistair |
Chief Operating Officer |
• – – |
2016-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
19,699 |
|
- |
|
| Macdonald D. Jamie |
Chief Executive Officer |
• • – |
2016-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
79,226 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
47,282 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-01-04 |
4 |
AS |
$46.47 |
$421,493 |
D/D |
(9,000) |
36,282 |
|
- |
|
| Gibertini Michael |
President Clinical Development |
• – – |
2016-01-04 |
4 |
OE |
$8.45 |
$76,050 |
D/D |
9,000 |
45,282 |
|
- |
|
| Macdonald Alistair |
Chief Operating Officer |
• – – |
2015-12-31 |
4 |
AS |
$46.64 |
$7,574,735 |
D/D |
(159,599) |
8,699 |
|
- |
|
| Macdonald Alistair |
Chief Operating Officer |
• – – |
2015-12-31 |
4 |
OE |
$8.45 |
$1,280,069 |
D/D |
112,617 |
37,103 |
|
- |
|
638 Records found
|
|
Page 22 of 26 |
|
|
